Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $6.00 target price on the stock.

Several other research firms have also recently issued reports on GANX. HC Wainwright reaffirmed a buy rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Thursday, July 11th. Oppenheimer reaffirmed an outperform rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Stock Up 1.5 %

Shares of Gain Therapeutics stock traded up $0.01 during midday trading on Friday, hitting $0.98. The company had a trading volume of 184,066 shares, compared to its average volume of 209,677. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.77 and a current ratio of 2.77. The stock has a market capitalization of $17.72 million, a P/E ratio of -0.65 and a beta of 0.35. The company has a 50 day moving average of $1.37 and a 200 day moving average of $2.87. Gain Therapeutics has a 52-week low of $0.92 and a 52-week high of $5.33.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, equities analysts predict that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors have recently bought and sold shares of GANX. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth $66,000. Renaissance Technologies LLC increased its stake in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth $422,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.